Investigational drug · Phase 2
ALKS 7290
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Attention Deficit Disorder With Hyperactivity (ADHD).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ALKS 7290"
First trial start
2026
Aug 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALKS 7290", any sponsor or status.
Conditions studied
As listed on its trial records.
- Attention Deficit Disorder With Hyperactivity (ADHD)
Approved drugs for the same conditions: ADHD · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ALKS 7290" as an intervention, largest first.
- A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07755410 · 312 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 2027
Drug: ALKS 7290; Placebo · For: Attention Deficit Disorder With Hyperactivity (ADHD)
Sites: Little Rock, Arkansas; Chino, California; Clermont, Florida · 28 sites in all
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07901179 · 180 participants (planned) · Start Nov 9, 2026 · Primary completion Jan 2028
Drug: ALKS 7290 Dose; Placebo · For: Major Depressive Disorder (MDD)
Sites: Jacksonville, Florida; North Canton, Ohio
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.